TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19034471
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dinoprostone vaginal insert for a maximum of 12 h
Study: 17523399
Drug: Allicor (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (a long‐action garlic‐based preparation) administered for 12 months
Study: 17523399
Drug: Allicor (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (a long‐action garlic‐based preparation)
Study: 15342615
Drug: Oral levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levosimendan 2 to 8 mg daily
Study: 11532109
Drug: Control (non-ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-ACE inhibitor regimens)
Study: 9778329
Drug: Implantable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class I
Study: 9778329
Drug: Implantable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class II
Study: 9778329
Drug: Implantable cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter-defibrillator (ICD) therapy in NYHA class III
Study: 3297521
Drug: Constant positive
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant positive airway pressure (CPAP) with an expiratory pressure of 12 cm H2O applied at one hour following extubation, and at daily intervals for the first five days following surgery for a continuous period of three hours
Study: 2201225
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intramuscularly followed by 10 mg 4-hourly as required
Study: 2201225
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg intramuscularly 4-hourly as required
Study: 31387559
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) and lung ultrasound (LUS)-guided antibiotic therapy
Study: 31387559
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) only-guided therapy
Study: 28203001
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft therapy combined with CGFs
Study: 28203001
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft therapy alone
Study: 26047892
Drug: Esmirtazapine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine 3.0 mg
Study: 26047890
Drug: Esmirtazapine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmirtazapine (all doses)
Study: 21692409
Drug: Proximal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal steroid injection (triamcinolone acetonide 20 mg)
Study: 21692409
Drug: Distal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal steroid injection (triamcinolone acetonide 20 mg)
Study: 19058842
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic drugs (amisulpride, clozapine, olanzapine, risperidone)
Study: 16436844
Drug: Arndt Blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arndt Blocker
Study: 9099195
Drug: Medium-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose aspirin
Study: 9099195
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (low-dose and medium-dose aspirin)
Study: 23992438
Drug: Breath Powered™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath Powered™ nasal delivery of 16-mg sumatriptan powder
Study: 23992438
Drug: 20-mg liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg liquid nasal spray
Study: 23992438
Drug: 100-mg oral
Normalized name: dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-mg oral tablet
Study: 23992438
Drug: 6-mg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mg subcutaneous injection
Study: 20971632
Drug: mIROX (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: mIROX (irinotecan plus oxaliplatin 85 mg/m(2))
Study: 20971632
Drug: FUFIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUFIRI (irinotecan 80 mg/m(2), 5‐fluorouracil 2000 mg/m(2), folinic acid 500 mg/m(2) weekly times 6)
Study: 17194276
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 to 60 mg/day
Study: 12094123
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g Cr.H2O
Study: 7572251
Drug: Daily lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lithium dosing (800 mg/day)
Study: 7572251
Drug: Every second
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every second day lithium dosing (1200 mg/every second day)
Study: 1971170
Drug: Ropinirol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirol 0.4 mg
Study: 1971170
Drug: Ropinirol 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirol 0.8 mg
Study: 1971170
Drug: Ropinirol 1
Normalized name: ropinirole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirol 1 mg
Study: 1971170
Drug: Ropinirol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirol (all doses)
Study: 33376
Drug: Diazepam (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5‐10 mg)
Study: 17458641
Drug: Bupivacaine continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine continuous epidural infusion with clonidine (5 microg.ml(‐1))
Study: 17458641
Drug: Bupivacaine continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine continuous epidural infusion without clonidine (control group)
Study: 17458641
Drug: Bupivacaine continuous
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine continuous epidural infusion with clonidine
Study: 474042
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cyproterone acetate
Study: 11994349
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cyproterone acetate
Study: 474042
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 months prior to treatment)
Study: 31352800
Drug: Statin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin group (40 mg atorvastatin daily for 7 days before operation)
Study: 25261291
Drug: lipegfilgrastim 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipegfilgrastim 6.0 mg
Study: 25261291
Drug: pegfilgrastim 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegfilgrastim 6.0 mg
Study: 22811596
Drug: Fluvastatin ER
Normalized name: fluvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin ER tablet 80 mg QD
Study: 22811596
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR capsule 40 mg BID
Study: 19238124
Drug: Aripiprazole 15-30
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15-30 mg/day
Study: 19238124
Drug: Haloperidol 10-15
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10-15 mg/day
Study: 17475739
Drug: Stepped treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped treatment initiated with buprenorphine/naloxone
Study: 17475739
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy
Study: 17475739
Drug: Stepped treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped treatment and Methadone maintenance therapy
Study: 15022801
Drug: Late weight-bearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late weight-bearing (L)
Study: 12500987
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg(‐1) before exercise and 0.33 mg.kg(‐1) every 15 min during exercise)
Study: 9536227
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle only) applied twice daily
Study: 9536227
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/g) with acitretin
Study: 9536227
Drug: Acitretin therapy
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin therapy
Study: 30678197
Drug: Telenutrition weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenutrition weight loss intervention with weekly support from a registered dietitian nutritionist via telephone and videoconferencing
Study: 24594505
Drug: Lutein (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (21 mg capsules with 250 mL of full-cream milk per day for 4 weeks)
Study: 24594505
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with 250 mL of full-cream milk per day for 4 weeks)
Study: 22510023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HbA(1c) 39-46 mmol/mol (5.7-6.4%) and fasting plasma glucose 5.6-6.9 mmol/l
Study: 22510023
Drug: Pre-diabetic individuals
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-diabetic individuals fulfilling HbA(1c) 42-46 mmol/mol (6.0-6.4%) and fasting plasma glucose 6.1-6.9 mmol/l
Study: 18207280
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy (n=14)
Study: 18207280
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) plus placebo monotherapy (n=16)
Study: 10770466
Drug: High-dose haloperidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose haloperidol with dose reduction to achieve target plasma level of 10 ng/mL over 12 weeks
Study: 10770466
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained original high-dose haloperidol treatment
Study: 9310019
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid treatment, budesonide 400 micrograms twice daily
Study: 31669136
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of GIP (50 pmol/kg body weight at 30 and 120 min)
Study: 31669136
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of GIP (2 pmol.kg-1.min-1 from 30 to 180 min)
Study: 31669136
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of GIP
Study: 31669136
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of GIP
Study: 27039386
Drug: E7820 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7820 50 mg BID
Study: 27039386
Drug: E7820 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7820 60 mg BID
Study: 27039386
Drug: E7820 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7820 100 mg QD
Study: 25208796
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) therapy, 15 minutes, 3 times per week for 7 months
Study: 20047610
Drug: Early reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early reduction of corticosteroid dose (prednisone 5 mg every other day for 12 months)
Study: 20047610
Drug: Regular-dose corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-dose corticosteroid maintenance (prednisone progressively reduced from days 8 to 90, then maintained for 12 months)
Study: 18692612
Drug: Regimen 1A
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1A (Dienogest dosage not specified)
Study: 18692612
Drug: Regimen 2A
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2A (Dienogest dosage not specified)
Study: 18692612
Drug: Regimen 2B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2B (Increased Dienogest dosage)
Study: 18692612
Drug: Regimen 2C
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2C (Increased Dienogest dosage)
Study: 11936481
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1a (IFNbeta-1a)
Study: 7860310
Drug: Exposed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposed group (cumulative radiation doses of about 500 mSv or more)
Study: 7860310
Drug: Unexposed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unexposed group (cumulative radiation doses less than 50 mSv)
Study: 7051507
Drug: Cinoxacin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin, 250 mg, qid for 7-14 days
Study: 27238963
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR twice-daily
Study: 23674935
Drug: Armodafinil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (150 mg/day)
Study: 23674935
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment after 6 weeks
Study: 22320027
Drug: Dextromethorphan and
Normalized name: Dextromethorphan and menthol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan and quinidine (DMQ) at doses of 0, 30, and 60 mg
Study: 22320027
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg DMQ)
Study: 15459950
Drug: Adhesive tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive tablets with natural active agents
Study: 15459950
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets (control)
Study: 9571269
Drug: DAILIES(TM) daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILIES(TM) daily disposable soft lenses for 8 hours
Study: 2644752
Drug: Heparin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (3 mg/kg bolus injection)
Study: 16813738
Drug: Insulin-sensitizing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitizing treatment strategies
Study: 16813738
Drug: Insulin-providing treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-providing treatment strategies
Study: 14517164
Drug: Eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 200 mg daily
Study: 14517164
Drug: Eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 200 mg and Enalapril 10 mg daily
Study: 8869672
Drug: Pipecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium 0.1 mg/kg
Study: 1642124
Drug: Standard bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bright morning light therapy (1700 lx) from 0600 to 0800
Study: 7198288
Drug: Restrictive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive treatment (bed rest in febrile stage, avoiding activities that promote headache)
Study: 7198288
Drug: Liberal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal treatment (encouraged to resume daily life as soon as possible)
Study: 29923314
Drug: RPR 102681
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 102681 (cholecystokinin-B antagonist)
Study: 11584088
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin A and iron supplementation (4800 retinol equivalents (RE) + 120 mg Fe as FeSO(4) + 500 microg folic acid)
Study: 11584088
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (120 mg Fe as FeSO(4) + 500 microg folic acid)
Study: 11584088
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin A and iron supplementation
Study: 9564665
Drug: GnRH-agonist therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-agonist therapy for three months
Study: 9564665
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment for three months
Study: 2671402
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HSL, Na 250 mEq/L, 514 mOsm)
Study: 2671402
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR, Na 130 mEq/L, 268 mOsm)
Study: 31796986
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor antagonist) 8 mg/kg every 4 weeks
Study: 31796986
Drug: Sitagliptin (DPP-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (DPP-4 inhibitor) 100 mg daily
Study: 31796986
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusion every 4 weeks and placebo pill once daily)
Study: 9514531
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsule)
Study: 23812094
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg per day
Study: 17697065
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.1 u/kg)
Study: 17697065
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (0.1 u/kg)
Study: 15318285
Drug: Cyriax approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyriax approach (CYR) - deep friction massage and mobilisation exercises three times weekly
Study: 15318285
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) - daily physical therapy including hot pack and short wave diathermy application
Study: 12441023
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants (first-line treatment)
Study: 12441023
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) during symptomatic luteal phase
Study: 12441023
Drug: Slow-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release formulation of fluoxetine (taken two times during the menstrual cycle)
Study: 12441023
Drug: New contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New contraceptive formulation
Study: 9789122
Drug: MLT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLT plus aloe vera tincture (1 ml twice/day)
Study: 9789122
Drug: MLT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLT alone (20 mg/day orally in the dark period)
Study: 2553335
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg 4-times daily
Study: 2553335
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 0.1 mg 4-times daily
Study: 2553335
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 puffs 4-times daily
Study: 793481
Drug: Levamisole at
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole at a dosage of 2.5 mg/kg/day
Study: 30366945
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT) - 1 Gray per fraction, administered six times in 2 weeks
Study: 30366945
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT)
Study: 24568907
Drug: Huangqi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huangqi injection (0.5 mL/kg·d for 35 days)
Study: 22777368
Drug: Uterosacral vault
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral vault suspension with perioperative pelvic floor muscle training
Study: 22777368
Drug: Uterosacral vault
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral vault suspension without perioperative pelvic floor muscle training
Study: 16054381
Drug: Protamine administered
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine administered 5 min after cardiopulmonary bypass
Study: 16054381
Drug: Protamine administered
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine administered 35 min after cardiopulmonary bypass
Study: 10418923
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - single oral dose (10^5.3 pfu)
Study: 10418923
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (DS-1 x UK) - single oral dose (10^5.8 pfu)
Study: 10418923
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (P x UK) - single oral dose (10^5.8 pfu)
Study: 10418923
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated human-bovine reassortant rotavirus vaccine (ST3 x UK) - single oral dose (10^5.8 pfu)